Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q905664> ?p ?o }
Showing triples 1 to 74 of
74
with 100 triples per page.
- Q905664 subject Q6870315.
- Q905664 subject Q8297710.
- Q905664 subject Q8413416.
- Q905664 subject Q8824860.
- Q905664 subject Q8852392.
- Q905664 subject Q8919936.
- Q905664 abstract "Sitaxentan sodium (TBC-11251) is a medication for the treatment of pulmonary arterial hypertension (PAH). It was marketed as Thelin by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan from the market due to concerns about liver toxicity.".
- Q905664 atcPrefix "C02".
- Q905664 atcSuffix "KX03".
- Q905664 bioavailability "70.0".
- Q905664 casNumber "184036-34-8".
- Q905664 casSupplemental "210421-64-0 (sodium salt)".
- Q905664 drugbank "DB06268".
- Q905664 fdaUniiCode "J9QH779MEM".
- Q905664 iupacName "N-(4-chloro-3-methyl-1,2-oxazol-5-yl)-2-[2-(6-methyl-2H-1,3-benzodioxol-5-yl)acetyl]thiophene-3-sulfonamide".
- Q905664 pubchem "216235".
- Q905664 thumbnail Sitaxsentan.svg?width=300.
- Q905664 wikiPageExternalLink article.php?article_id=1420.
- Q905664 wikiPageExternalLink presenter.jhtml?identifier=4752.
- Q905664 wikiPageExternalLink 1860.
- Q905664 wikiPageExternalLink thelin_050714.html.
- Q905664 wikiPageWikiLink Q1057.
- Q905664 wikiPageWikiLink Q10916362.
- Q905664 wikiPageWikiLink Q1128595.
- Q905664 wikiPageWikiLink Q1349821.
- Q905664 wikiPageWikiLink Q1359801.
- Q905664 wikiPageWikiLink Q14864419.
- Q905664 wikiPageWikiLink Q14916181.
- Q905664 wikiPageWikiLink Q152234.
- Q905664 wikiPageWikiLink Q178436.
- Q905664 wikiPageWikiLink Q179217.
- Q905664 wikiPageWikiLink Q1869874.
- Q905664 wikiPageWikiLink Q191521.
- Q905664 wikiPageWikiLink Q1988322.
- Q905664 wikiPageWikiLink Q204711.
- Q905664 wikiPageWikiLink Q2047938.
- Q905664 wikiPageWikiLink Q206921.
- Q905664 wikiPageWikiLink Q207843.
- Q905664 wikiPageWikiLink Q2622199.
- Q905664 wikiPageWikiLink Q305481.
- Q905664 wikiPageWikiLink Q30612.
- Q905664 wikiPageWikiLink Q3245488.
- Q905664 wikiPageWikiLink Q3443277.
- Q905664 wikiPageWikiLink Q390566.
- Q905664 wikiPageWikiLink Q390709.
- Q905664 wikiPageWikiLink Q407431.
- Q905664 wikiPageWikiLink Q412474.
- Q905664 wikiPageWikiLink Q419769.
- Q905664 wikiPageWikiLink Q6870315.
- Q905664 wikiPageWikiLink Q8297710.
- Q905664 wikiPageWikiLink Q8413416.
- Q905664 wikiPageWikiLink Q86.
- Q905664 wikiPageWikiLink Q8824860.
- Q905664 wikiPageWikiLink Q8852392.
- Q905664 wikiPageWikiLink Q8919936.
- Q905664 wikiPageWikiLink Q9368.
- Q905664 wikiPageWikiLink Q9377.
- Q905664 atcPrefix "2.0".
- Q905664 atcSuffix "KX03".
- Q905664 bioavailability "70".
- Q905664 casNumber "184036".
- Q905664 casSupplemental "210421".
- Q905664 drugbank "DB06268".
- Q905664 iupacName "N--2-[2-acetyl]thiophene-3-sulfonamide".
- Q905664 pubchem "216235".
- Q905664 unii "J9QH779MEM".
- Q905664 type ChemicalSubstance.
- Q905664 type Drug.
- Q905664 type ChemicalObject.
- Q905664 type Thing.
- Q905664 type Q8386.
- Q905664 comment "Sitaxentan sodium (TBC-11251) is a medication for the treatment of pulmonary arterial hypertension (PAH). It was marketed as Thelin by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan from the market due to concerns about liver toxicity.".
- Q905664 label "Sitaxentan".
- Q905664 depiction Sitaxsentan.svg.